BayFort Capital
In Part-I of this series of articles, we discussed how the Insulin delivery system is an Oligopoly between Medtronic, Tandem, and Insulet. In Part II of this series, we discussed the TAM and growth opportunities for the Insulin delivery systems segment. Insulin delivery...
The FTC has a critical enforcement weapon it can use to block acquisitions and pressure merging parties to abandon deals the regulators dislike — administrative adjudication. These are lengthy trials conducted before the agency in its own court, not in federal court. This...
In Part-I of this series of articles, we discussed how the US Insulin delivery systems market is an Oligopoly between Tandem, Medtronic & Insulet. In this article, we will discuss the Insulin delivery system’s total addressable market (TAM) and some factors which could...
The US Insulin delivery system space is dominated by three players Tandem, Insulet, and Medtronic. DexCom and a few other companies provide Continuous Glucose Monitoring (CGM) devices used by Insulin delivery systems. In this article, we will discuss this niche and many times...
We have heard a lot of criticism from economists about how other central banks around the world are slow in increasing interest rates and that they should follow the US Federal Reserve to stabilize their respective currencies and control inflation. The simple answer...
Revenues: EL’s Asia Pacific (China is the bulk of it) Revenues have grown at a CAGR of 14% over the last three years (ending June 22) in spite of it being flat in TTM due to covid lockdowns in China. Pre-pandemic they were...

Stay informed about BayFort Capital